The combination of alnodesertib and irinotecan shows promising efficacy in ATM-negative metastatic colorectal cancer, with a ...
The investigational, potentially first-in-class agent tinostamustine (EDO-S101) has earned FDA orphan drug designation (ODD) ...
During a live event, Thomas G. Martin, MD, discussed updated findings from the CARTITUDE-1 trial of cilta-cel and what they signify for patients with no disease progression at 5 years.
The FDA has cleared a phase 3 trial for lacutamab in CTCL, following promising phase 2 results showing durable activity and safety. TELLOMAK 3 will assess progression-free survival with two cohorts: ...
The FDA approves a new diagnostic tool enhancing precision treatment for advanced endometrial carcinoma, improving patient outcomes with targeted therapies. The FDA has approved the OncoMate® MSI Dx ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback